

Daniela Tomasoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6024836/publications.pdf>

Version: 2024-02-01

55
papers

3,160
citations

361045

20
h-index

360668

35
g-index

55
all docs

55
docs citations

55
times ranked

6259
citing authors

#	ARTICLE	IF	CITATIONS
1	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 "epidemiology, pathophysiology, and diagnosis. European Heart Journal, 2022, 43, 1033-1058.	1.0	80
2	Sex-related differences in patients with coronavirus disease 2019. Journal of Cardiovascular Medicine, 2022, Publish Ahead of Print, 254-263.	0.6	3
3	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 348.	1.0	5
4	Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Tj ETQq0 0 0 rgBT /Overlock 14	0.7	14
5	January 2022 at a glance: time for the new <sc>ESC</sc> guidelines on heart failure. European Journal of Heart Failure, 2022, 24, 1-3.	2.9	0
6	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs, 2022, 82, 375-405.	4.9	7
7	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 "epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	1.8	27
8	March 2022 at a glance: focus on medical therapy, prevention and comorbidities. European Journal of Heart Failure, 2022, 24, 403-405.	2.9	1
9	Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Failure, 2022, 9, 1507-1523.	1.4	26
10	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <sc>ACTIVE</sc> study, an <sc>Italian nationwide survey</sc>. European Journal of Heart Failure, 2022, 24, 1377-1386.	2.9	43
11	April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 593-595.	2.9	0
12	May 2022 at a glance. Focus on treatment: from epidemiologic data to randomized trials and new devices. European Journal of Heart Failure, 2022, 24, 735-737.	2.9	0
13	Prognostic impact of the updated 2018 <sc>HFA-ESC</sc> definition of advanced heart failure: results from the <sc>HELPEHF</sc> registry. European Journal of Heart Failure, 2022, 24, 1493-1503.	2.9	22
14	Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study. Journal of Cardiovascular Medicine, 2022, 23, 439-446.	0.6	6
15	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. Clinical Research in Cardiology, 2021, 110, 1020-1028.	1.5	32
16	January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity. European Journal of Heart Failure, 2021, 23, 1-2.	2.9	0
17	The Altmetric Attention Score: how science tries to meet social media. European Journal of Heart Failure, 2021, 23, 693-697.	2.9	5
18	Evidence-Based Management of Acute Heart Failure. Canadian Journal of Cardiology, 2021, 37, 621-631.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation. <i>Current Heart Failure Reports</i> , 2021, 18, 99-106.	1.3	20
20	May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 691-692.	2.9	0
21	June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment. <i>European Journal of Heart Failure</i> , 2021, 23, 847-849.	2.9	0
22	July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy. <i>European Journal of Heart Failure</i> , 2021, 23, 1059-1061.	2.9	0
23	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. <i>Europace</i> , 2021, 23, 1603-1611.	0.7	34
24	The prognostic value of serial troponin measurements in patients admitted for COVID-19. <i>ESC Heart Failure</i> , 2021, 8, 3504-3511.	1.4	25
25	Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 108, 270-273.	1.5	6
26	August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices. <i>European Journal of Heart Failure</i> , 2021, 23, 1247-1249.	2.9	0
27	Vericiguat for Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , 2021, 23, 144.	1.3	19
28	Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 3547-3556.	1.4	29
29	COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 713560.	1.1	76
30	September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment. <i>European Journal of Heart Failure</i> , 2021, 23, 1419-1421.	2.9	0
31	Congestion in Patients with Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 575-586.	1.0	13
32	Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy. <i>European Journal of Heart Failure</i> , 2021, 23, 486-488.	2.9	2
33	October 2021 at a glance: focus on imaging, biomarkers and comorbidities. <i>European Journal of Heart Failure</i> , 2021, 23, 1569-1571.	2.9	0
34	November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices. <i>European Journal of Heart Failure</i> , 2021, 23, 1803-1805.	2.9	0
35	Unmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
36	Clinical characteristics and outcomes of a contemporary, real-world, single-centre cohort of patients with advanced heart failure. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0

#	ARTICLE	IF	CITATIONS
37	December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models. European Journal of Heart Failure, 2021, 23, 1993-1994.	2.9	0
38	A year in heart failure: an update of recent findings. ESC Heart Failure, 2021, 8, 4370-4393.	1.4	28
39	566â€¦Transthyretin and light-chain cardiac amyloidosis: clinical characteristics, echocardiographic findings, and outcomes of a large cohort of patients in Northern Italy. European Heart Journal Supplements, 2021, 23, .	0.0	0
40	July 2020 at a glance: focus on imaging and cardiomyopathies. European Journal of Heart Failure, 2020, 22, 1057-1059.	2.9	0
41	Heart failure in the last year: progress and perspective. ESC Heart Failure, 2020, 7, 3505-3530.	1.4	52
42	November 2020 at a glance: focus on comorbidities and medical treatment. European Journal of Heart Failure, 2020, 22, 1937-1938.	2.9	1
43	Impact of heart failure on the clinical course and outcomes of patients hospitalized for <scp>COVID</scp>â€¦19. Results of the <scp>Cardioâ€¦COVIDâ€¦Italy</scp> multicentre study. European Journal of Heart Failure, 2020, 22, 2238-2247.	2.9	99
44	Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction. Journal of Cardiovascular Medicine, 2020, 21, 874-881.	0.6	38
45	September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy. European Journal of Heart Failure, 2020, 22, 1493-1494.	2.9	0
46	August 2020 at a glance: focus on neurohormonal antagonists and electrolytes. European Journal of Heart Failure, 2020, 22, 1289-1290.	2.9	0
47	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1274.	3.0	157
48	October 2020 at a glance: focus on outcomes, valve disease and patients' monitoring. European Journal of Heart Failure, 2020, 22, 1745-1746.	2.9	0
49	Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European Heart Journal, 2020, 41, 1821-1829.	1.0	434
50	<scp>COVIDâ€¦</scp>19 and heart failure: from infection to inflammation and angiotensin <scp>II</scp> stimulation. Searching for evidence from a new disease. European Journal of Heart Failure, 2020, 22, 957-966.	2.9	208
51	Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombusâ€¦A New Indication? A Meta-summary of Case Reports. Journal of Cardiovascular Pharmacology, 2020, 75, 530-534.	0.8	30
52	Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 2020, 5, 819.	3.0	1,465
53	Inâ€¦hospital and longâ€¦term mortality for acute heart failure: analysis at the time of admission to the emergency department. ESC Heart Failure, 2020, 7, 2650-2661.	1.4	26
54	December 2020 at a glance: focus on <scp>COVID</scp>â€¦19, comorbidities and palliative care. European Journal of Heart Failure, 2020, 22, 2173-2174.	2.9	2

#	ARTICLE	IF	CITATIONS
55	Highlights in heart failure. ESC Heart Failure, 2019, 6, 1105-1127.	1.4	109